1
Stanley M Crain, Ke fei Shen: Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other opioid agonists. Albert Einstein College of Medicine of Yeshiva University, Amster Rothstein & Ebenstein, December 5, 1995: US05472943 (131 worldwide citation)

This invention relates to a method of selectively enhancing the analgesic potency of morphine and other clinically used bimodally-acting opioid agonists and simultaneously attenuating development of physical dependence, tolerance and other undesirable side-effects caused by the chronic administratio ...


2
Stanley M Crain, Ke fei Shen: Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists. Albert Einstein College of Medicine of Yeshiva University, Amster Rothstein & Ebenstein, August 1, 2000: US06096756 (124 worldwide citation)

This invention relates to a method for selectively enhancing the analgesic potency of a bimodally-acting opioid agonist such as morphine and simultaneously attenuating anti-analgesia, hyperalgesia, hyperexcitability, physical dependence and/or tolerance effects associated with the administration of ...


3
Stanley M Crain, Ke Fei Shen: Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by exogenous and endogenous opiod agonists. Albert Einstein College of Medicine of Yeshiva University a Division of Yeshiva University, Amster Rothstein & Ebenstein, April 30, 1996: US05512578 (101 worldwide citation)

This invention relates to a method of selectively enhancing the analgesic potency of morphine and other clinically used bimodally-acting opioid agonists and simultaneously attenuating development of physical dependence, tolerance and other undesirable side effects caused by the chronic administratio ...


4
Stanley M Crain, Ke fei Shen: Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists. Albert Einstein College of Medicine of Yeshiva University a Division of Yeshiva University, Amster Rothstein & Ebenstein, December 3, 1996: US05580876 (95 worldwide citation)

This invention relates to a method for selectively enhancing the analgesic potency of a bimodally-acting opioid agonist such as morphine and simultaneously attenuating anti-analgesia, hyperalgesia, hyperexcitability, physical dependence and/or tolerance effects associated with the administration of ...


5
Stanley M Crain, Ke fei Shen: Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists. Albert Einstein College of Medicine of Yeshiva University a Division of Yeshiva University, Amster Rothstein & Ebenstein, June 16, 1998: US05767125 (91 worldwide citation)

This invention relates to a method for selectively enhancing the analgesic potency of a bimodally-acting opioid agonist such as morphine and simultaneously attenuating anti-analgesia, hyperalgesia, hyperexcitability, physical dependence and/or tolerance effects associated with the administration of ...


6
Stanley M Crain, Ke fei Shen, John A Kessler, Stuart C Apfel: Use of excitatory opioid receptor antagonists to prevent growth factor-induced hyperalgesia. Albert Einstein College of Medicine of Yeshiva University a Division of Yeshiva University, Amster Rothstein & Ebenstein, December 17, 1996: US05585348 (83 worldwide citation)

This invention relates to a method of preventing hyperalgesia and other undesirable side-effects associated with the administration of growth factor, including nerve growth factor, utilizing an antagonist capable of inactivating excitatory opioid receptor-mediated functions on neurons in the nocicep ...


7
Stanley M Crain, Ke fei Shen, Gerald M Fleischner: Method and composition for treating irritable bowel syndrome using low doses of opioid receptor antagonists. Albert Einstein College of Medicine of Yeshiva University, Amster Rothstein & Ebenstein, February 27, 2001: US06194382 (64 worldwide citation)

This invention relates to a method for eating a subject with irritable bowel syndrome (“IBS”) which comprises long-term administration of an opioid receptor antagonist at an appropriately low dose which will selectively antagonize excitatory opioid receptor functions, but not inhibitory opioid recep ...


8
Bo yi Qin, Ke fei Shen, Xiong qi Gong, Stanley M Crain, Mao Huang, Chang Yi Wang: Method for identification of low/non-addictive opioid analgesics and the use of said analgesics for treatment of opioid addiction. United Biomedical, Morgan & Finnegan L, April 29, 1997: US05624932 (62 worldwide citation)

The present invention relates to a method of using a bioassay consisting of an electrophysiological method and a cell culture system of dorsal-root ganglion (DRG) neurons to screen and identify opioids with a high potential for use as "low- or non-addictive" analgesics. Another aspect of the inventi ...


9
Stanley M Crain, Ke fei Shen, Gerald M Fleischner: Method and composition for treating irritable bowel syndrome using low doses of opioid receptor antagonists. Albert Einstein College of Medicine of Yeshiva University, Amster Rothstein & Ebenstein, May 28, 2002: US06395705 (61 worldwide citation)

This invention relates to a method for treating a subject with irritable bowel syndrome (“IBS”) which comprises long-term administration of an opioid receptor antagonist at an appropriately low dose which will selectively antagonize excitatory opioid receptor functions, but not inhibitory opioid rec ...


10
Stanley M Crain, Ke Fei Shen, Barry Sherman, Mary Remien, Remi Barbier, Nadav Friedmann: Compositions and methods for enhancing analgesic potency of tramadol and attenuating its adverse side effects. Pain Therapeutics, Albert Einstein College of Medicine of Yeshiva University, McAndrews Held & Malloy, July 20, 2004: US06765010 (58 worldwide citation)

The invention generally relates to compositions and methods with tramadol and an opioid antagonist to enhance analgesic potency and/or attenuate one or more adverse effects of tramadol, including adverse side effect(s) in humans such as nausea, vomiting, dizziness, headache, sedation (somnolence) or ...